OSA
7 by improving levels of daytime alertness and well-being through alleviating upper airway obstruction and returning sleep quality and blood oxygen levels to normal. The major goal of OSA treatment has been to relieve patients of debilitating daytime sleepiness and socially disruptive snoring, and for patients who initially accept CPAP therapy, long-term adherence is 70-80%. 8 However, there has been increasing evidence of a causal relationship between OSA and CV disease through several potential pathways of physiological disturbance during sleep. 9 Animals exposed to intermittent hypoxia similar to those experienced by patients with OSA have shown sustained elevations in BP, central nervous system damage, and abnormalities of glucose and lipid metabolism. [10] [11] [12] [13] Clinical and community-based studies have shown OSA to be independently associated with hypertension, glucose dysregulation, and ischemic and cerebrovascular disease.
14-18 Shortterm CPAP treatment of OSA has been shown to result in small reductions in systemic 19, 20 and pulmonary artery blood pressure, 21, 22 and improvements in some other biomarkers of CV risk, 23 but not all such intervention studies had been positive. 24 A large longitudinal but nonrandomized study completed prior to the launch of SAVE suggested that CPAP therapy might substantially reduce the risk of CV events.
OSA and incident CV disease [25] [26] [27] [28] [29] [30] [31] and mortality, [32] [33] [34] [35] further strengthening the rationale for the trial. Larger randomized controlled trials with longer follow-up have also confirmed small BP reductions with CPAP. 19, 36, 37 There thus exists substantial evidence that OSA may increase the risk of premature CV disease including myocardial infarction and stroke, and that CPAP treatment may reduce these risks. However, there are many examples in medicine where non-randomized studies pointed strongly to a likely benefit of a particular therapeutic intervention (e.g., vitamin E and CV disease, hormone replacement therapy and CV disease, and most recently of renal denervation and hypertension) only for large-scale clinical trials to subsequently show no benefit, or even harm, from such treatment. [38] [39] [40] [41] A large-scale, hard endpoint, randomized controlled trial is therefore required to determine whether the pathophysiological disorder of OSA has a modifiable effect on premature CV disease.
The need for adequately powered clinical trials of OSA treatment focused on CV outcomes was well recognized in the late 2000s. 9, 42 The 2008 joint American Heart Association and American College of Cardiologists Foundation scientific statement on sleep apnea 9 concluded that although the association between OSA and CV disease appears strong, the observational nature of much of the evidence and the possibility of residual confounding by visceral obesity weakened the overall case in favor of a causal link. The statement concluded that rigorous intervention studies in support of a benefit from OSA treatment were missing, which hampered progress in this field, a view that has been strongly endorsed by a more recent international consensus statement. 43 The SAVE trial was therefore designed to bridge this gap.
Clinical Equipoise
The Steering Committee consulted widely with respiratory and CV physicians in several countries in their design of the SAVE study to gauge the level of uncertainty over whether to prescribe OSA treatment specifically for CV risk reduction in adults with established CV disease. Not surprisingly, a wide range of opinions were obtained but consensus at the time was that there was insufficient evidence to recommend OSA treatment routinely for CV risk reduction. Substantial clinical equipoise existed on this question during [2005] [2006] [2007] [2008] , and it has not changed sufficiently to alter the opinion of the SAVE investigators or the broader international sleep medicine community.
Background Planning
Planning for the SAVE study began in 2006 assisted by a research grant from the Respironics Foundation. An academic partnership was formed between Australian sleep and respiratory clinicians-scientists at the Adelaide Institute for Sleep Health (AISH) of Flinders University and investigators at The George Institute of Global Health of the University of Sydney, to prepare the ground work for the trial. With considerable experience in large-scale international CV clinical trials (e.g., ADVANCE and INTERACT 1 and 2 44, 45 ), The George Institute was able to provide the necessary expertise and research infrastructure to mount a study of this size. The AISH had considerable experience in clinical sleep research and, with the assistance of the Australasian Sleep Trials Network, provided the necessary expertise in sleep apnea diagnosis and CPAP treatment. With equipment grants from the sleep diagnostic and device companies Compumedics and ResMed, a necessary preliminary study to test the validity of a simple screening device for diagnosing OSA in potentially eligible patients for the trial was conducted in Shanghai. 46 After further engagement with experts in sleep, respiratory, and CV disease around the world, the study design and research plan were finalized. Further funding from the Respironics Foundation then allowed the study to proceed.
Trial Design
The SAVE study was designed as an international, multicenter, open, blinded endpoint assessment, randomized controlled trial to determine whether treatment of OSA with CPAP on top of best medical care compared to best medical care alone can reduce the risk of serious CV events in patients with established CV disease. In order for the results to be able to influence clinical practice, the study was powered to detect a treatment effect on hard CV endpoints that included myocardial infarction and stroke rather than surrogate markers of CV risk such as blood pressure (BP), lipids and glucose metabolism. Moreover, given multiple overlapping potential pathogenic pathways whereby OSA may lead to CV events, we considered this approach assessing the effects of CPAP treatment on a composite of downstream CV events was preferable to assuming a dominant mechanism(s) for increased CV risk.
We considered it impractical to continue patients randomized to the control group on sham CPAP over several years. The control group is thus usual care and the study an open label one. To allow for other factors that may affect cardiovascular outcomes (e.g., weight change, use of antihypertensive medication) and that could potentially differ between the two groups during the study, we are tracking medication changes and lifestyle modifications such as patient weight, level of exercise, and smoking history throughout the trial.
Because of the relatively high rate of CV events in patients with established CV disease, the number of patients required to assess the treatment effects in a secondary prevention trial is less. If we assume a 1% annual event rate in a primary prevention trial we would need two to three times as many participants. Although a secondary prevention trial in OSA might target some pathogenic mechanisms that are less relevant to primary CV disease prevention (e.g., sudden nocturnal death due to ventricular tachycardia/fibrillation in patients with existing ischemic heart disease), it nevertheless provides highly relevant information to inform clinical practice with plausible translation of results into primary prevention. Furthermore, the smaller sample size and shorter duration of exposure to assess effects on outcomes provides reassurance about feasibility and efficiency in completing such a trial. Table 1 summarizes the primary and secondary endpoints in the SAVE study, and Figure 1 outlines the overall design schema. The primary endpoint is a composite of CV events that includes CV death, nonfatal myocardial infarction, nonfatal stroke, and any hospitalization (or presentation at hospital to allow detailed diagnostic assessment) for unstable angina, heart failure, or transient ischemic attack (TIA). Based on prior studies in similar high risk populations, the event rate for this composite endpoint was estimated at 6% per annum. Table 2 summarizes the eligibility criteria for the SAVE study. Patients were included with established CV disease and co-occurring moderate-severe OSA that was diagnosed by a simple overnight screening device (Apnea Link, Resmed, Bella Vista Sydney, Australia) which also allowed other forms of sleep disordered breathing (e.g., obesity hypoventilation syndrome, overlapping hypoxemic lung disease or Cheyne-Stokes Respiration (CSR) to be excluded on the basis of the pattern of nasal airflow disturbance, awake resting and overnight oximetry measurement, and other clinical features. Patients were also excluded if they were judged to be very sleepy or if they reported a sleepiness-related accident in the previous 6 months (see ethical issues in the following paragraphs).
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Patient Inclusion and Exclusion Criteria
Patient Recruitment
We recognized that recruitment would be a challenging component of SAVE where patients require screening for a diagnosis of OSA. Despite the high frequency (30-60%) of OSA in groups with high CV risk, 9 , [48] [49] [50] [51] we estimated that two to three patients with 
Exploratory analyses
To address potential mechanisms of CV event reduction the following parameters will be assessed at baseline and at 6 mo, and 2 and 4 y following randomization (except for ECG being performed at baseline, 24 mo, and at the end of patient follow-up), in a subsample of approximately 600 patients. existing CV disease would need to be screened to identify one eligible patient (i.e., 10,000-15,000 patients) to achieve the required sample size. We realized this would not be easily achieved by relying solely on referrals to sleep medicine services, where patients with OSA are generally symptomatic, expect to be offered treatment, and have a low frequency of comorbid CV disease. Although recruiting patients directly from CV clinics was more attractive, this would require CV/ stroke clinicians to develop new skills in OSA diagnosis and CPAP treatment and/or form strong collaborative working relationships with local respiratory/sleep services. We therefore decided to extend an invitation to a wide range of these Table 2 -Subject eligibility and recruitment procedures.
To be eligible for entry into SAVE, patients must satisfy the following criteria: • Previous stroke (includes definite or presumed cerebral ischemia/infarction and intracerebral, but not subarachnoid hemorrhage) ≥ 90 days prior to ApneaLink assessment; or minor disabling stroke with minimal residual neurological disability (modified Rankin score of "0 = no symptoms" or "1 = no significant disability despite symptoms, able to carry out all usual duties and activities" within 7 days of stroke onset) ≥ 7 days prior to ApneaLink assessment.
• Previous transient ischemic event (TIA) of the brain or retina (standard definition symptoms < 24 h), but not of presumed vertebrobasilar system ischemia. The TIA diagnosis must be confirmed by a suitably neurologically qualified clinician ≥ 7 days to < 1 y prior to ApneaLink assessment. • Severe chronic obstructive pulmonary disease (forced expiratory volume (FEV 1 )/forced vital capacity (FVC) < 70% and FEV 1 < 50% predicted), or • Resting, awake oxygen saturation (SaO 2 ) ≤ 90% by ApneaLink device 4. New York Heart Association (NYHA) categories III-IV of heart failure 5. Other household member enrolled in SAVE trial or using CPAP 6. Prior use of CPAP treatment for OSA 7. Increased risk of a sleep related accident and/or excessive daytime sleepiness, defined by any one of the following:
• Driver occupation (e.g. truck, taxi)
• "Fall-asleep" accident or "near-miss" accident in previous 12 mo • High (> 15) score on the Epworth Sleepiness Scale 8. Severe nocturnal desaturation documented on the ApneaLink device as
• > 10% overnight recording time with arterial oxygen saturation of < 80% 9. Cheyne-Stokes Respiration (CS Resp)
• CS Resp identified on ApneaLink nasal pressure recording by typical crescendo-decrescendo pattern of respiration with associated apneas and/or hypopneas in the absence of inspiratory flow limitation.
• Patients are excluded if > 50% of nasal pressure--defined apneas and hypopneas judged to be due to CS Resp because such patients are unlikely to have sleep disordered breathing completely reversed by CPAP.
clinician groups to participate in the study, provide training and support in sleep diagnostics and CPAP therapy where needed, and encourage collaboration at national and local levels. Such interdisciplinary collaboration will be needed if the results of the SAVE study prove to be positive.
DIAGNOSIS OF OSA BY AMBULATORY SLEEP APNEA MONITORING
In-laboratory polysomnography (PSG) was not feasible for screening and diagnosing OSA in such a large number of participants required for the SAVE study. Moreover, many potential recruitment sites in China do not have access to PSG and most sleep medicine services elsewhere are heavily booked with clinical work. Even if PSG facilities could be made available at sites, we considered the cost and effort to train staff and standardize recording and scoring techniques between laboratories (or centralise scoring) was prohibitive for the type of study envisioned. There was increasing evidence that simplified home screening devices could be used to identify moderate-severe OSA with a high degree of certainty, at least in populations with high pretest probability of disease, with many sleep experts advocating such an approach in clinical practice and research. 52 Because the frequency of OSA in the proposed study population was likely to be high, it was decided to validate a simple, automated two-channel (oximetry and nasal pressure) screening device (the ApneaLink, ResMed) in a high CV risk community setting in China with the view to using this device in the main study. This China-Australian collaborative validation study showed that the automatically calculated oxygen desaturation index (oximetry) and apnea-hypopnea index (AHI) (nasal pressure) had equally high diagnostic accuracy for moderatesevere OSA when compared with full PSG simultaneously performed in the homes of 143 patients at high risk of CV in Shanghai. Because the ApneaLink Oximetry had a lower technical failure rate (e.g., loss of signal because of sensor displacement) than nasal pressure recordings, it was the preferred primary diagnostic method for identifying patients with OSA for SAVE. 46 The nasal pressure trace can be used to exclude patients whose predominant pattern of sleep disordered breathing pattern is symmetrical waxing and waning of flow indicating possible CSR. An algorithm was developed by the study core laboratory at the Adelaide Institute for Sleep Health (AISH) to identify patients with predominantly CSR using nasal pressure signals from the ApneaLink device (Table 3 ). Subsequent enhancement of ApneaLink software has also proved useful in this regard.
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ETHICAL AND SAFETY CONCERNS
Excessive Daytime Sleepiness and Accident Risk
The main ethical question was whether withholding CPAP treatment in patients who screen positive for OSA and have the potential to benefit from improved daytime vigilance and wellbeing would place them at significant risk of future accident. To minimize such risk, it was decided to exclude patients who held a commercial driver's licence, reported an accident (or nearmiss accident) because of sleepiness in the previous 6 mo, or who had marked daytime sleepiness as evident by high scores (> 15) on the Epworth Sleepiness Scale (ESS) ( Table 2) . Additionally, systems were developed to closely monitor patient safety during the course of follow-up, where all patients are asked about any recent accidents or uptake of employment as a commercial driver, and the ESS questionnaire was completed at each study visit. The core laboratory monitors the following key data: if an ESS is found to exceed 15 in either usual care or CPAP-treated patients, a simple pro forma questionnaire is used to collect information on possible contributors to daytime sleepiness covering sleep patterns and estimated total sleep time, sedative medications or excessive alcohol use, emergent depression, or in the case of those on CPAP, the adequacy of therapy in terms of adherence and control of OSA. The core laboratory director then communicates either directly with the principal investigator of the relevant site to advise on the management of the excessive sleepiness, or in China indirectly via a sleep expert independent of the SAVE study to assist and adjudicate on cases where there remains clinical uncertainty as to the cause of daytime sleepiness. The intent is to ensure that severely sleepy patients are not prevented from receiving a potentially effective therapy, yet at the same time avoiding unnecessary crossover from the usual care arm to CPAP by carefully considering and managing causes of sleepiness deemed not to be primarily related to OSA. At enrollment, all patients were fully informed about the nature of the study and the possible symptomatic benefits of CPAP and the option to seek treatment outside of the trial if they wished. Both the patient and his or her Table 3 -Procedure for checking Cheyne-Stokes respiration pattern.
• Each ApneaLink file is manually checked.
• Cheyne-Stokes respiration (CSR) is defined as crescendo-decrescendo pattern of breathing for at least three consecutive cycles • If CSR breathing is identified, it is edited (highlighted) manually.
• CSR is then calculated and recorded as a proportion of total events:
• 0-10%, 10-30%, 30-50%, 50-70%, or > 70%.
• Files identified as having CSR breathing are then checked for flow limitation:
• The breaths of each CSR cycle are first divided into thirds with the start of the cycle defined as the onset of the apnea. The middle one-third breaths are excluded from examination because arousal typically occurs in this part of the CSR cycle and could be expected to eliminate sleep related flow limitation. Breaths in the first and last third of the cycle are examined for flow limitation. If > 50% of these breaths are judged to show inspiratory flow limitation, this whole CSR cycle is excluded as being obstructive in nature.
• The remaining CSR cycles without obstruction are then calculated and recorded as a proportion of total events: 0-10%, 10-30%, 30-50%, 50-70%, and > 70%.
• Patients in whom > 50% of all sleep disordered breathing events are judged to be nonobstructive CSR are excluded from further participation in SAVE.
responsible physician were required to be comfortable about random allocation to CPAP treatment or usual care.
Patients with Very Severe OSA
Another concern was whether, despite equipoise regarding the advisability of OSA treatment for CV risk reduction, it was reasonable to deny CPAP treatment to patients with very severe OSA. Following discussions with the lead investigators, it was decided to exclude patients whose overnight oximetry study showed > 10% of the time with oxygen saturations < 80%. These patients were recommended for further investigation and/or treatment by their physician independent of the study.
Conduct of Clinical Trials in Low Resource Settings
There has been debate about the ethics of investigators or pharmaceutical companies from advanced economies conducting clinical trials of relatively complex or expensive treatments in socioeconomically disadvantaged populations where treatments are either not relevant to their health care system or are so expensive as to put them beyond the reach of most of the population. The 2002 statement by the Nuffield Council of Bioethics report provided us with useful guidance on these ethical issues in designing the study. The statement recommends that: 54 • studies respect the cultural values of host countries and the rights of the participants to be fully informed and to give their consent willingly without coercion or undue inducement; • the research, wherever possible, should be relevant to the host country and is not detrimental to the health or welfare of the participants; • the development of local expertise in health care is integral to the conduct of the research and that any changes are sustainable in the local context after the research is completed; and • the sponsoring researchers do not take advantage of the vulnerabilities created by poverty, or lack of infrastructure or resources. A guiding principle is that there should be a thorough process of consultation with clinicians and researchers in the host countries and, if necessary, the government or health authorities in those countries. Also, ethics committees in both the sponsoring and host countries must approve the protocols.
We consider the SAVE study meets these recommendations after we undertook detailed discussions with key opinion leaders in sleep, respiratory, and CV medicine in each of the participating countries to ensure the study protocol adheres to ethical and regulatory standards, was sensitive to cultural norms, and that the research question being addressed was relevant to local health care needs. CV disease is the major cause of mortality in developing as well as developed countries and will increase in line with the demographic transitions of aging, urbanization, and adoption of Western lifestyles. Thus, the findings from the SAVE study will be highly relevant to future health care in the host countries, with the simple home diagnostic technique for detecting OSA ideally suited for routine care in large populations with limited health care resources. Agreement was reached with Philips Respironics to ensure CPAP treatment would be available to the control group, should the results prove positive at the end of the study. The study has been approved by the Ethics Committees of all the participating sites in each of the host countries.
Use of a Sham Run-in Phase
Another issue we considered was that adherence to CPAP therapy might be a significant problem in a study lasting over several years, particularly considering that most subjects were likely to report little or no daytime sleepiness and therefore would be unlikely to experience significant symptomatic benefit. In addition, clinical studies indicate that as many as 30% of patients with OSA refuse CPAP treatment outright or in the first few weeks of therapy. 55 To exclude those patients who would be unwilling or unlikely to adhere to CPAP therapy, we decided to use a 1-w sham CPAP run-in phase. Sham CPAP is designed to deliver only a very low, nontherapeutic pressure to the airway, 56 and previous clinical studies have shown similar short-term adherence levels with sham and active CPAP. We assumed that if patients were sufficiently motivated and able to wear a CPAP mask for a minimum average period of 3 h per night, they would be more likely to comply with active treatment in the long term. The inclusion of a sham device runin phase prior to randomization is consistent with other longterm clinical trials that aim to maximize efficiency in detecting a treatment effect by excluding people who are unable to tolerate the treatment or adhere to procedures, 57 and in the case of OSA it simulates current clinical practice in which patients are frequently offered an initial trial of CPAP to ascertain their acceptance or otherwise of the treatment.
RANDOMIZATION
Randomization was Web based via a password-protected, fully secure study website. A minimization program was used to stratify treatment allocation by site, type of CV disease (cardiac or cerebrovascular) and by a measure of daytime sleepiness severity (ESS score < 11 or ≥ 11). After eligibility in the study was confirmed, the patient was registered and assigned to a particular randomised group.
CPAP Commencement and Follow-up
Patients randomized to receive CPAP were given further written information about the treatment and were asked to watch a short DVD designed to educate them about the importance of the trial and adherence to CPAP. Next, they were provided with an AutoPAP machine (M or PR series Remstar, Phillips Respironics, Murrayville, PA) from which data were downloaded via smart cards after 1 w to check that it was technically satisfactory, and that the average usage time was > 3 h per night, with average leak < 60 L/min. If patients failed to meet these criteria, any technical or mask-fit problems were resolved and the patient was asked to repeat the study. After this a fixed CPAP pressure was set at the 90 th centile pressure, patients received a telephone call after 1 w to troubleshoot any difficulties and at later times if any problems arose. All participants were reviewed at 1, 3, and 6 mo, and contacted 6 months thereafter until the close of the study. The core laboratory monitors trends in CPAP adherence stratified by country, site, and patient levels. An automatic email is sent to the site investigator if any of their patients show any of the following conditions: CPAP usage drop to < 3 h per night, high mask leak (> 60 L/min), or high (> 15/h) residual AHI as measured by the CPAP device. The core laboratory also provides a helpline for specifi c advice to investigators.
Sample Size Calculations
We originally estimated that 5,000 patients would need to be recruited to detect a 20% relative risk (RR) reduction in the primary endpoint in the CPAP group compared with the usual care group with 80% power (α 0.05) assuming: (1) a 2-y recruitment period with an average follow-up of 4 y; (2) 6% annual event rate for the primary endpoint, and (3) loss to follow-up of 10% in each arm. A meta-regression of the association between AHI and the risk of CV disease based on data extracted from fi ve prior epidemiological studies available in 2008 4, 16, 17, 27, 58 suggested that the risk of CV events increased by 16% for every 10 events per hour increase in AHI. We estimated that a 32% RR reduction in major CV events would occur among participants in SAVE who are likely to have a mean AHI of 45 events per hour (American Academy of Sleep Medicine "Chicago" scoring criteria) or an oxygen desaturation index (> 3%, 30 events per hour) that would be decreased to about 25 events per hour with CPAP treatment, assuming an average usage of 3-4 h per night. However, the trial was powered more conservatively to detect a 20% RR reduction (α 0.05, β 0.80) to allow for potential for 20% non adherence to treatment and 10% loss to follow-up in each group.
In 2012, we reassessed the assumptions inherent in the power calculation based upon: (1) a review of the accumulated blinded study data, specifi cally the severity of OSA in participants, adherence to CPAP, the overall primary CV endpoint rate and loss to follow-up; and (2) an updated meta-regression of longitudinal studies of CV events according to OSA severity (AHI) which shows that CV risk increases by 25-32% for every 10 events per hour increase in AHI from 19 to 29 ( Figure 3) . This relationship is considerably stronger than our original estimate, and agrees closely with another regression analysis by Loke et al. 59 that reported that a 10-unit incremental increase in AHI was associated with an odds ratio (OR) of 1.36 (95% confidence interval [CI] 1.26 to 1.43) for the outcomes of stroke and CV death (Figure 2 ).
Adherence to CPAP treatment was also greater than we had initially expected, varying from an average of 3-3.5 h per night (including the patients who had ceased using CPAP) in July 2012. At this time, the average oxygen desaturation index (ODI) at baseline was 28/h (which approximates to an AHI of ~35-40/h) but was expected to decrease by approximately 15/ hour with CPAP adherence at an average of 3-3.5 h/night by the end of the study. The overall primary un adjudicated CV event rate was 6.08%, which would equate to an event rate of 6.86% in the usual care group if our underlying assumptions over the potential treatment effect were correct.
The updated power calculation indicated a sample size of 2,500 would be needed to detect a 25% RR reduction (α 0.05, β 0.80) in the primary composite CV endpoint. Assumptions inherent in this calculation were: (1) updated recruitment period of 5 y; (2) an average follow-up of 4.5 y and a minimum follow-up of 2 y for the last patient recruited at the end of 2013; (3) an annual event rate in the usual care group of 6.86%; and (4) an average CPAP adherence of 3 h per night. Based on these considerations the Executive Committee recommended that the study be repowered to detect a 25% reduction in the RR of the primary composite CV event endpoint.
PROGRESS OF THE SAVE STUDY
Funding for the trial has included a grant of US$5million from the Respironics Foundation in 2008 and grants of Figure 2 -Predicted odds ratio for cardiovascular events based on metaregression coeffi cients (n = 7 studies). Two researchers independently conducted literature searches for papers on the association of sleep apnea and cardiovascular disease/events. Studies needed to report adjusted odds or hazard ratios (OR, HR) stratifi ed by groups with reports of mean apnea-hypopnea index (AHI) or range of AHI in the stratifi cation. Twenty-four studies were identifi ed, 17 were excluded (2 were cross sectional studies, 12 did not report on a composite cardiovascular outcome, e.g., only stroke, one was a subsequent publication of the same population included, one had no stratifi cation or reports of AHI, one reported RDI only), and seven studies were included in the meta-regression. One researcher extracted data and conducted the meta-regression on the log OR/HR. Normal probability plot of shrunken residuals was conducted to confi rm that there were no notable outliers as such a normal random effects model was suffi cient. Sensitivity analyses were conducted removing the cross-sectional study. All analyses were conducted using STATA version 12. From the meta-regression coeffi cients it is possible to estimate the log OR of cardiovascular event (CVE) at a given AHI using the formula log OR = 0.1321137 + 0.0223362AHI. Based on the coeffi cients from the meta-regression we calculated that for a drop in AHI from 29 to 19 the resulting CVE risk reduction is 25%. Campos-Rodriguez (2012) 29 Marin (2005) 16 Martinez-Garcia (2012) 30 Moe (2001) 4 Shah (2010) 35 Takama (2009) 31 Young (2008) Figure 3 shows the pattern of enrollment over the 5-y recruitment phase, with 62% of patients included from China. We initially envisioned recruiting 0.8-1.0 patients per site per month but this proved difficult to achieve and despite minor protocol amendments in 2009, 2011, and 2013 designed to lessen the burden of data collection and data entry on investigators, and expansion of the international network to include sites in India (2010) Spain (2011), USA (2011), and Brazil (2012), the average rate of recruitment remained at 0.7 per active site per month equating to a total of 45 per month. Impediments to recruitment varied over time, and between sites and countries. The major difficulty reported by investigators related to the complexity and time consuming nature of the screening process. Despite changes made in early 2009 to reduce the amount of data collection and entry, the study still required a necessary and unavoidable high level of technical competency covering the diagnosis of OSA, use of the sham CPAP run-in, and implementation of therapeutic (and adherent) CPAP. Access to a suitable high CV risk patient pool was also a problem at some sites. Generally, recruitment was highest at sites with both ready access to the required type of patients and a highly motivated and organized study coordinator with sufficient time to devote to research. We tried to maximize investigator engagement through regular communications by newsletter, meetings, and telephone calls to highlight the importance of the study, report on progress, and suggest strategies to overcome barriers. The addition of the Spanish and Brazilian sites to the study has bolstered recruitment and offset investigator fatigue in other countries.
We recently reported trial data showing intention-to-treat average daily CPAP adherence of 3.3 h at 12 mo 60 which exceeds our original estimates and is greater than has been reported in other CV populations. [61] [62] [63] [64] Investigators remained blind to all CV outcome data. The challenge is to maintain or, if possible, increase CPAP adherence for the remainder of the trial. The current "better-than-expected" adherence is likely caused by a combination of factors: use of a sham run-in phase to exclude subjects unable to tolerate mask treatment; an OSA study population which by virtue of the serious nature of their CV problems is motivated to comply with the study procedures despite OSA symptoms; and the intensive training and support in CPAP therapy provided to site investigators.
TRIAL MANAGEMENT
The trial is managed by an Executive Committee (Appendix) with overall responsibility for the design and conduct of the study and an Operations Committee is responsible for day-to-day operational matters. A Principal Investigator (PI) for each participating country or region advises these Committees on relevant national regulatory issues, clinical practice standards, and patient recruitment strategies. The CV trials expertise and management skills of The George Institute have been crucial to the successful conduct of the study. Project Managers in each country provide valuable links with investigators and are able to advise and monitor issues that are often country specific and which may not be readily identifiable to either the Principal Investigator or Operations Committee staff based in Australia. For example, CPAP usage was limited at times in some cities in India due to frequent planned nocturnal power outages used to manage stretched power grids. As staff in some countries had limited experience and training in OSA and CPAP therapy, we needed to provide comprehensive start-up training in sleep medicine, OSA and CPAP, and extensive and ongoing support and education during the course of the trial.
An independent Data Safety Monitoring Board (DSMB) also monitors rates of self-reported accidents in the CPAPtreated and usual care groups. As part of their regular oversight of the study, the DSMB is responsible for safeguarding the interests of trial participants, assessing the safety and efficacy of the interventions during the trial, and for monitoring the overall conduct of the trial. The DSMB has met annually to review study progress, has undertaken one planned interim analysis, and concurred with the Executive Committee's decision to reduce the sample size. It has not identified any safety concerns to date and has recommended continuation of the trial.
SUMMARY AND CONCLUSIONS
As the largest clinical trial in the field of sleep apnea research to date, SAVE would not have been made possible without the early start-up and ongoing support from industry and peer-reviewed competitive research grant funding from the NHMRC of Australia. However, our study has been conceived and designed independent of the sponsors and the SAVE Investigators have autonomy with respect to the conduct of the study and in analysing and reporting of the data. We believe the SAVE trial is of considerable interest to the fields of sleep, respiratory, and CV medicine. Our projections are that the last patient visit will occur in late 2015 and the main results will be announced in late 2016. If the results prove that the treatment of OSA reduces the risk of CV events in a high-risk patient group, it will pave the way for a paradigm shift in CV disease management with global reach.
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